← Russell 3000 cross-section

AMGN AMGEN INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$238.1bn
Revenue TTM
$38.1bn
Net income TTM
$8.7bn
Free cash flow
$10.2bn
Composite score
55.9
Sector rank
#49

Valuation

P / E
27.2
EV / EBITDA
17.2
EV / sales
7.2
FCF yield
4.27%
Earnings yield vs 10-yr
-1.06pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
22.9%
EBITDA margin
42.2%
ROE
74.8%
ROIC
23.1%
Revenue growth
9.1%

Insider activity, last 90 days

Net open-market
$-4.11m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Prolia Total Prolia sales by geographic region were as follows (dollar amounts in millions): The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively. For the remainder of 2026, we continue to expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW. EVENITY Total EVENITY sales by geographic region were as follows (dollar amounts in millions): The increases in global EVENITY sales for the three and six months ended June 30, 2026 were driven by volume growth. …AMGEN INC, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →